OPTIMER PHARMACEUTICALS INC Forms 3, 4 and 5: Preferred Stock
Statements of beneficial ownership filed with the SEC by officers, directors and 10% owners: 35 rows, 35 shown. Transaction codes are the SEC's. Shares and prices are split-adjusted; the as-filed figure is underneath.
- 2007-02-14: Reporting owner Che Tessie M; Form 4; Security Series A Preferred Stock; Transaction C Conversion of derivative security.
- 2007-02-14: Reporting owner Che Tessie M; Form 4; Security Series B Preferred Stock; Transaction C Conversion of derivative security.
- 2007-02-14: Reporting owner Che Tessie M; Form 4; Security Series D Preferred Stock; Transaction C Conversion of derivative security.
- 2007-02-14: Reporting owner Chang Michael N; Form 4; Security Series A Preferred Stock; Transaction C Conversion of derivative security.
| Transaction date | Reporting owner | Form | Security | Transaction | Shares | Price | Price that day | Filing |
|---|---|---|---|---|---|---|---|---|
| 2007-02-14 | Che Tessie M Officer (SVP, Corporate Affairs) | 4 | Series A Preferred Stock Derivative · Direct | C Conversion of derivative security | −92,306 0 owned after | $0.00 | 2007-02-14 | |
| 2007-02-14 | Che Tessie M Officer (SVP, Corporate Affairs) | 4 | Series B Preferred Stock Derivative · Direct | C Conversion of derivative security | −8,306 0 owned after | $0.00 | 2007-02-14 | |
| 2007-02-14 | Che Tessie M Officer (SVP, Corporate Affairs) | 4 | Series D Preferred Stock Derivative · Direct | C Conversion of derivative security | −113,535 0 owned after | $0.00 | 2007-02-14 | |
| 2007-02-14 | Chang Michael N Director, Officer (President, CEO) | 4 | Series A Preferred Stock Derivative · Indirect · By spouse | C Conversion of derivative security | 0 owned after | $0.00 | 2007-02-14 | |
| 2007-02-14 | Chang Michael N Director, Officer (President, CEO) | 4 | Series B Preferred Stock Derivative · Indirect · By spouse | C Conversion of derivative security | 0 owned after | $0.00 | 2007-02-14 | |
| 2007-02-14 | Chang Michael N Director, Officer (President, CEO) | 4 | Series P Preferred Stock Derivative · Indirect · By spouse | C Conversion of derivative security | 0 owned after | $0.00 | 2007-02-14 | |
| 2007-02-14 | SCHREIBER ALAIN Director | 4 | Series B Preferred Stock Derivative · Indirect · By ProQuest Investments II, L.P. | C Conversion of derivative security | −737,911 0 owned after | $0.00 | 2007-02-14 | |
| 2007-02-14 | SCHREIBER ALAIN Director | 4 | Series B Preferred Stock Derivative · Indirect · By ProQuest Investments II Advisors Fund, L.P. | C Conversion of derivative security | −31,305 0 owned after | $0.00 | 2007-02-14 | |
| 2007-02-14 | SCHREIBER ALAIN Director | 4 | Series D Preferred Stock Derivative · Indirect · By ProQuest Investments II, L.P. | C Conversion of derivative security | −295,164 0 owned after | $0.00 | 2007-02-14 | |
| 2007-02-14 | SCHREIBER ALAIN Director | 4 | Series D Preferred Stock Derivative · Indirect · By ProQuest Investments II Advisors Fund, L.P. | C Conversion of derivative security | −12,522 0 owned after | $0.00 | 2007-02-14 | |
| 2007-02-14 | Chow Joseph Director | 4 | Series B Preferred Stock Derivative · Indirect · By SB Life Science Ventures I, L.P. | C Conversion of derivative security | −492,298 0 owned after | $0.00 | 2007-02-14 | |
| 2007-02-14 | Chow Joseph Director | 4 | Series D Preferred Stock Derivative · Indirect · By SB Life Science Ventures I, L.P. | C Conversion of derivative security | −76,921 0 owned after | $0.00 | 2007-02-14 | |
| 2007-02-14 | Lee Howard Director | 4 | Series B Preferred Stock Derivative · Indirect · By Formosa Healthcare Investments, L.P. | C Conversion of derivative security | −769,218 0 owned after | $0.00 | 2007-02-14 | |
| 2007-02-14 | Lee Howard Director | 4 | Series D Preferred Stock Derivative · Indirect · By Formosa Healthcare Investments, L.P. | C Conversion of derivative security | −372,301 0 owned after | $0.00 | 2007-02-14 | |
| 2007-02-14 | Par Pharmacuetical, Inc. 10% Owner | 4 | Series C Preferred Stock Derivative · Direct | C Conversion of derivative security | −2,307,655 0 owned after | $0.00 | 2007-02-14 | |
| 2007-02-14 | Shue Youe Kong Officer (VP, Clinical Development) | 4 | Series B Preferred Stock Derivative · Indirect · By Spouse | C Conversion of derivative security | −5,538 0 owned after | $0.00 | 2007-02-14 | |
| 2007-02-14 | Muenchbach Martin Director | 4 | Series D Preferred Stock Derivative · Indirect · By BB Biotech Ventures II, L.P. | C Conversion of derivative security | −769,218 0 owned after | $0.00 | 2007-02-14 | |
| 2007-02-08 holding as of filing | Shue Youe Kong Officer (VP Clinical Development) | 3 | Series B Preferred Stock Derivative · Indirect · (m) | Holding | no price filed | 2007-02-08 | ||
| 2007-02-08 holding as of filing | Shue Youe Kong Officer (VP Clinical Development) | 3 | Series D Preferred Stock Derivative · Indirect · (m) | Holding | no price filed | 2007-02-08 | ||
| 2007-02-08 holding as of filing | SCHREIBER ALAIN Director | 3 | Series B Preferred Stock Derivative · Indirect · (m) | Holding | no price filed | 2007-02-08 | ||
| 2007-02-08 holding as of filing | SCHREIBER ALAIN Director | 3 | Series D Preferred Stock Derivative · Indirect · (m) | Holding | no price filed | 2007-02-08 | ||
| 2007-02-08 holding as of filing | SCHREIBER ALAIN Director | 3 | Series B Preferred Stock Derivative · Indirect · (m) | Holding | no price filed | 2007-02-08 | ||
| 2007-02-08 holding as of filing | SCHREIBER ALAIN Director | 3 | Series D Preferred Stock Derivative · Indirect · (m) | Holding | no price filed | 2007-02-08 | ||
| 2007-02-08 holding as of filing | Par Pharmacuetical, Inc. 10% Owner | 3 | Series C Preferred Stock Derivative · Direct | Holding | no price filed | 2007-02-08 | ||
| 2007-02-08 holding as of filing | Muenchbach Martin Director | 3 | Series D Preferred Stock Derivative · Indirect · (m) | Holding | no price filed | 2007-02-08 | ||
| 2007-02-08 holding as of filing | Lee Howard Director | 3 | Series B Preferred Stock Derivative · Indirect · (m) | Holding | no price filed | 2007-02-08 | ||
| 2007-02-08 holding as of filing | Lee Howard Director | 3 | Series D Preferred Stock Derivative · Indirect · (m) | Holding | no price filed | 2007-02-08 | ||
| 2007-02-08 holding as of filing | Chow Joseph Director | 3 | Series B Preferred Stock Derivative · Indirect · (m) | Holding | no price filed | 2007-02-08 | ||
| 2007-02-08 holding as of filing | Chow Joseph Director | 3 | Series D Preferred Stock Derivative · Indirect · (m) | Holding | no price filed | 2007-02-08 | ||
| 2007-02-08 holding as of filing | Che Tessie M Officer (Senior VP, Corporate Affairs) | 3 | Series A Preferred Stock Derivative · Direct · (m) | Holding | no price filed | 2007-02-08 | ||
| 2007-02-08 holding as of filing | Che Tessie M Officer (Senior VP, Corporate Affairs) | 3 | Series B Preferred Stock Derivative · Direct · (m) | Holding | no price filed | 2007-02-08 | ||
| 2007-02-08 holding as of filing | Che Tessie M Officer (Senior VP, Corporate Affairs) | 3 | Series D Preferred Stock Derivative · Direct · (m) | Holding | no price filed | 2007-02-08 | ||
| 2007-02-08 holding as of filing | Chang Michael N Director, Officer (President & CEO) | 3 | Series A Preferred Stock Derivative · Indirect · (m) | Holding | no price filed | 2007-02-08 | ||
| 2007-02-08 holding as of filing | Chang Michael N Director, Officer (President & CEO) | 3 | Series B Preferred Stock Derivative · Indirect · (m) | Holding | no price filed | 2007-02-08 | ||
| 2007-02-08 holding as of filing | Chang Michael N Director, Officer (President & CEO) | 3 | Series D Preferred Stock Derivative · Indirect · (m) | Holding | no price filed | 2007-02-08 |